Bio-Rad slides ahead of April 30 earnings as caution builds after Citi downgrade
Bio-Rad Laboratories shares fell about 3% on April 28, 2026 as investors positioned ahead of its Q1 2026 earnings report due after the close on April 30. Recent analyst action, including a Citigroup downgrade to Neutral with a lower price target in April, has also weighed on sentiment into the print.
1) What’s moving the stock today
Bio-Rad Laboratories (BIO) traded lower Tuesday, April 28, 2026, with the decline aligning with a pre-earnings de-risking move ahead of the company’s first-quarter 2026 results due after the market close on Thursday, April 30. With the earnings event two sessions away, positioning and options hedging often magnify modest negative bias—especially for stocks that have recently faced more cautious sell-side commentary. (investors.bio-rad.com)
2) The near-term overhang: more cautious analyst tone
Adding to the risk-off setup, Bio-Rad has faced a shift in analyst sentiment in April after Citigroup moved its rating from Buy to Neutral and cut its price target. That downgrade has kept attention on whether Bio-Rad can re-accelerate instrument demand and defend margins in a mixed research-funding backdrop. (simplywall.st)
3) What investors will watch on April 30
The April 30 report and conference call will be judged on (1) revenue growth and segment mix between Life Science and Clinical Diagnostics, (2) operating margin trajectory, and (3) the outlook commentary for the rest of 2026. Bio-Rad’s most recent full-year update pointed to modest 2026 currency-neutral revenue growth expectations, leaving limited room for disappointment if demand trends soften or costs run hotter than expected. (investing.com)